Infected Blood Compensation Scheme

Clive Efford Excerpts

Thursday 13th February 2025 Commons Chamber

[Nick Thomas-Symonds]

I will make sure that your stricture about time is properly communicated across Government, Madam Deputy Speaker.

May I start by echoing the comments of the hon. Member for Kingswinford and South Staffordshire (Mike Wood) about my predecessor as Paymaster General, the right hon. Member for Salisbury (John Glen), who did so much in government to push this forward? Just as I offered cross-party support when shadowing him, the continued cross-party support today is very important in respect of the speed at which we are able to push forward with the legal framework we are putting in place.

On the issue of speed, I am restless for progress. While IBCA is of course an arm’s length body and has operational independence, I will none the less have more to say in due course about key performance indicators, as the House will want to continue to raise the speed of payments being made to constituents.

I entirely agree with the hon. Gentleman’s comments about clarity of communication. I am forever emphasising the need for simple explainer documents on what are complex regulations. Finally, the Government have already allocated £11.8 billion in funding for the operation of IBCA and for compensation, and we are committed to compensate all the victims of this terrible scandal.

[Clive Efford (Eltham and Chislehurst) (Lab)]

I welcome my right hon. Friend’s statement and the progress he has made in seven months, not least on the £11.8 billion he secured in the Budget; he deserves credit for that. It is regrettable that we lost a year from Sir Brian Langstaff’s second interim report in which he gave his final recommendations on compensation, stating that the Government had no reason to delay setting up the compensation process. I know my right hon. Friend is aware that there are still concerns about the tariff, particularly among those infected with hepatitis C and those who endured unethical testing. Does he agree that, while we must move ahead with all haste to get people the justice they deserve, IBCA must have flexibility in its decisions when dealing with those who feel that the tariff does not recognise the suffering they have endured?

[Nick Thomas-Symonds]

I pay tribute to my hon. Friend for the work he does as chair of the all-party parliamentary group on haemophilia and contaminated blood. Obviously the tariffs were set on the basis of the expert group chaired by Sir Jonathan Montgomery and I compliment him on the work he did in that regard. However, the tariffs and the scheme also recognise particular individual circumstances and cases that are more complex. That is why the supplemental route is being put in place. I would add that I saw when I visited IBCA—I understand that my hon. Friend will be visiting shortly—the sympathetic, compassionate approach being taken with regard to evidence, given how long ago so much of this happened.